Mito Health is best for self-directed breadth and price discovery — choose your own markers, browse a large catalogue, and compare nearby labs. Marek Diagnostics is best for expert-designed optimization panels built from a broad biomarker library. AMORTAL is neither: it takes whichever you choose and turns the results into one ranked next action, a watchlist, and an outcome loop.
Mito Health and Marek Diagnostics both serve advanced, optimization-minded lab buyers — but they’re built on different bets. Mito leans into self-directed breadth and price discovery: you choose what to test, browse a large catalogue of markers, book a nearby lab, compare pricing, and get clinician-reviewed next steps. Marek leans into expert-designed optimization panels — curated panels plus custom builds from a broad biomarker library, with direct access to labwork.
Both answer “what do my numbers look like?” well, in their own way. Neither is built to answer the harder question that comes next: an advanced panel surfaces lots of slightly-off markers, and the risk is turning every abnormality into an action. So what should you actually change, what should you ignore, and when do you retest? That’s the gap this page is about — and where AMORTAL fits, on top of whichever one you pick. It’s educational, not medical advice.
vs
+
Use Mito or Marek for the testing. Use AMORTAL to decide what the data should change, what to ignore, what to watch, and when to retest — without turning every slightly-off marker into an action.
The short version: who each is for
Two of these produce optimization data in different shapes; the third decides what to do with whichever you have. Here’s the honest split.
Which one fits which job
Mito HealthBest for price discovery + breadthA self-directed route: choose your own markers, browse a broad catalogue (Mito advertises 1,000+), book a nearby lab and compare pricing, with clinician-reviewed next steps. Strongest when you want breadth and control over what you pay and where you draw.
Marek DiagnosticsBest for expert-designed optimization panelsExpert-designed optimization panels plus custom panels built from a large library (Marek advertises 100+ biomarkers), with direct access to labwork. Strongest when you want a curated, optimization-focused panel rather than assembling one yourself.
AMORTALBest for deciding what to do nextNot a lab. A longitudinal decision layer that reads whatever results you already have — from either provider — and returns one ranked next action, a watchlist, a clinician-ready question, and an outcome loop. Including when to do nothing.
This isn't an "A beats B." Mito and Marek answer what are my numbers in different shapes — self-directed breadth versus expert-designed panels; AMORTAL answers what should they change. The strongest setup is one provider plus AMORTAL.
Mito vs Marek vs AMORTAL, at a glance
Tap between the three to see what each is actually responsible for.
What each one owns
Same goal — better decisions from optimization labs — split into two ways of getting data and one decision layer.
Mito — self-directed breadth
A self-directed testing route: choose your own markers from a broad catalogue (Mito advertises 1,000+), book a nearby lab, compare pricing across labs, and receive clinician-reviewed next steps.
You want breadth, control over what you test, and the ability to compare lab pricing before you book. Verify the current marker catalogue, pricing and lab coverage before buying.
Marek — expert-designed panels
Expert-designed optimization panels plus custom panels built from a large biomarker library (Marek advertises 100+), with direct access to labwork rather than assembling a panel yourself.
You want a curated, optimization-focused panel designed for you rather than self-directing the choices. Verify the current panels, biomarker list and pricing before buying.
AMORTAL — the decision layer
Not a lab. It takes either provider's results, normalises them into a memory, and produces one ranked next action, a watchlist, a clinician-ready question, and an outcome loop — with restraint built in.
You already have results and the real question is "what now?" — what to change, what to ignore, what to watch, and when a retest is actually worth it, rather than acting on every slightly-off marker.
AMORTAL has no direct integration with either — you bring the data in by upload or manual entry.
The comparison, row by row
| Dimension | Mito Health | Marek Diagnostics | AMORTAL |
|---|---|---|---|
| Best use case | Self-directed breadth + price discovery | Expert-designed optimization panels | Deciding what the data should change |
| Collection method | Choose your markers; book nearby labs | Curated + custom panels; direct labwork | No draws — works from results you have |
| Panel design | You self-direct what to test | Expert-designed + custom panels (advertised) | Doesn’t design panels; decides on the results |
| Biomarker breadth | Broad catalogue (advertises 1,000+ markers) | Panels from 100+ biomarkers (advertised) | Doesn’t test; reads whatever you bring |
| Lab partner / processing | Compare pricing across nearby labs (advertised) | Direct access to labwork (as advertised) | Lab-agnostic; vendor-neutral |
| Wearable integration | Not the core product | Not the core product | Connects labs to Oura / Whoop / Apple Watch |
| Upload existing labs | Its own ordering flow | Its own panels | Yes — bring either provider’s results in |
| Clinician review | Clinician-reviewed next steps (advertised) | Optimization-focused review (as advertised) | Clinician-compatible questions; not a clinician |
| Action plan depth | Clinician-reviewed next steps | Expert panel guidance | One ranked next best action, plus restraint |
| Retesting cadence | Re-order when you choose | Panel-driven cadence | Tells you when not to retest yet |
| Result trend tracking | Within its own results | Within its own panels | Longitudinal memory across providers and time |
| Abnormal-result handling | Flags + clinician-reviewed steps (advertised) | Flagged in an optimization context (as advertised) | Safety-gated; routes urgent flags to a clinician |
| Cost model | Pay per test / lab pricing (verify current) | Panel pricing (verify current) | Decision layer — founding membership |
| Where AMORTAL fits | Self-directed breadth in | Expert-designed panel data in | → ranked decision, watchlist, outcome loop out |
Provider rows describe what each company publicly advertises as of June 2026 — pricing, marker counts, panels and included features change often, so confirm current details on each provider's own pages before buying. Sources are at the foot of this page.
Which one fits what you actually want
| What you want | Reach for |
|---|---|
| To self-direct what I test and compare lab prices | Mito Health |
| The broadest catalogue to browse and choose from | Mito Health |
| An expert-designed optimization panel I don’t assemble myself | Marek Diagnostics |
| A curated panel from a large biomarker library | Marek Diagnostics |
| I already have results — tell me what to do next | AMORTAL |
| To not turn every slightly-off marker into an action | AMORTAL |
| To rank one next step instead of changing five things | AMORTAL |
| A clinician-ready question, not a treatment directive | AMORTAL |
| To know whether I should retest yet | AMORTAL |
| To track whether a change actually worked | AMORTAL |
Where AMORTAL fits — whichever you pick
The model is the same regardless of which route you choose: let the provider do the testing, then run the result through a decision process instead of a dashboard.
- Bring the result in. Upload your Mito or Marek report, or enter the key markers — there's no direct integration, so you carry the data over.
- Normalise into memory. AMORTAL files each biomarker into a longitudinal record, not a one-off screen.
- Connect the context. Results are linked to your goals, symptoms, wearables, medications and constraints.
- Activate the standards. The guidelines and decision rules that actually apply to your situation switch on.
- Produce a Decision Contract. One change at a time, with the expected signal and the window written down in advance.
- Rank one Next Best Action. Not ten. The single highest-value move — which may be "do nothing yet."
- Set the watchlist. Markers worth re-checking get an expected direction and a recheck window — slightly-off markers go on watch, not on a to-do list.
- Close the loop. When the next panel or outcome signal arrives, AMORTAL checks whether the action worked — and keeps or discards it.
A decision loop, end to end
Here’s the same flow on a single example — illustrative numbers only, not a target or a reference range.
From a result to a tracked outcome
Your Mito or Marek panel comes back with a dozen markers flagged slightly outside range — including a marginally elevated ferritin your clinician notes is worth attention. On a wall of red and yellow numbers, the temptation is to act on all of them at once.
AMORTAL files each marker next to your prior results, goals, medications and wearable trends — read as trajectories, not a screen full of one-off dots.
One lever, not twelve. The single marker most worth acting on, the signal you'd expect it to move, and the window to see it are written down before anything changes.
Framed as a clinician-ready question — "given this trend, is [one specific lever] the right first move?" — not a treatment directive AMORTAL has no authority to give. The other slightly-off markers go on watch, not on a to-do list.
Each borderline marker gets an expected direction and a recheck window — so you retest when it's informative, not because a panel lit up yellow.
At the next draw, AMORTAL checks: did the one change move the signal as expected? If yes, it earns its place. If not, it's dropped — no story told over normal variation.
AMORTAL doesn't diagnose and isn't a substitute for your clinician — anything urgent goes to a professional, now.
Mito or Marek — which fits you?
If you’re choosing between the two, this narrows it. Whichever you land on, AMORTAL sits on top of it.
Mito, Marek, or is the decision the real job?
How do you want to choose what to test?
What's your bigger risk right now?
Mito fits self-directed breadth and price discovery. Verify the current catalogue and lab pricing, get the draw, then bring the results into AMORTAL so breadth doesn't become noise — one ranked next step instead of a long list of yellow numbers.
Marek fits expert-curated optimization panels. Verify the current panels and pricing, then use AMORTAL to keep you from acting on every slightly-off marker — it ranks one next step and tracks whether it worked.
If over-testing is the risk, the lab matters less than the decision discipline. Pick Mito or Marek on price and fit, then let AMORTAL rank one next step, set a watchlist, and track whether the change actually worked.
Where each is strongest — and where it isn’t
In fairness to all three:
- Mito is strongest when you want self-directed breadth and the ability to compare lab pricing before you book — and less ideal if you’d rather not assemble the panel yourself, or if your bottleneck is deciding on data you already have.
- Marek is strongest when you want an expert-designed optimization panel from a large biomarker library without doing the curation yourself — and less ideal if you want maximum control over individual markers and lab pricing.
- Verify before you buy. Marker counts, panels, prices and included features change for both — confirm the current details on each provider’s own pages.
- Breadth is a beginning, not an answer. Advanced panels surface many slightly-off markers; some will need a clinician, and AMORTAL should never be read as a diagnosis, whichever provider produced the number.
Bring your results into a decision, not a dashboard
AMORTAL doesn’t need to be where you buy your blood tests. The stronger model is to let a provider like Mito or Marek do the testing, then use AMORTAL as the longitudinal decision system around those results. Upload the report, or enter the markers that matter. AMORTAL turns the result into memory, evaluates what’s still missing, ranks the next best action, sets a watchlist for the signals to expect, and later checks whether the action actually worked — without turning every abnormality into an action.
Already have results from Mito Health or Marek Diagnostics? Bring them into AMORTAL and ask the only question that matters: “What should I do next?”
Sources
Provider claims describe what each company publicly advertised when this page was last fact-checked (26 June 2026). Pricing, marker counts, panels and included features are volatile — verify on the official pages before purchase.
Mito Health — self-directed testing claims: choose markers, browse the catalogue, book nearby labs, compare pricing, and clinician-reviewed next steps.
Marek Diagnostics — expert-designed and custom optimization panels built from a large biomarker library, with direct access to labwork.
Marek — detail on panels, biomarkers and how the optimization labwork is handled.
Educational only — this is not medical advice or a diagnosis. Talk to a licensed clinician about your own numbers, targets, and any treatment decisions.
Frequently asked
Mito Health vs Marek Diagnostics — which should I choose?
It depends on how you want to choose what to test. Mito is strongest when you want to self-direct — pick your own markers from a broad catalogue, book a nearby lab, and compare pricing, with clinician-reviewed next steps. Marek is strongest when you'd rather an expert designs an optimization panel for you, with custom panels built from a large biomarker library and direct access to labwork. Both publish claims and pricing that change often — verify the current details before buying. Whichever you pick, AMORTAL works on top of the results.
Can AMORTAL work with results from either Mito or Marek?
Yes. AMORTAL is lab-agnostic and works from results you already have — you bring them in by uploading the report or entering key markers (there's no direct integration with either). It normalises the biomarkers into a longitudinal memory, connects them to your goals, wearables and protocols, and returns one ranked next action rather than another dashboard. The provider you chose stays your data source; AMORTAL is the decision layer.
Does AMORTAL replace Mito Health or Marek Diagnostics?
No. They do a different job. Mito and Marek order, run and review optimization labs; AMORTAL decides what that data should change, what to ignore, what to watch, and when to retest. Most people who use AMORTAL keep their provider for the testing and use AMORTAL to turn each result into an auditable decision and an outcome loop.
Should I pick my own markers (Mito) or let experts design the panel (Marek)?
Both are reasonable, and they suit different buyers. Self-directing through Mito gives you breadth and price control — useful if you know what you want and want to compare lab pricing. An expert-designed Marek panel removes the assembly work and leans on a curated optimization approach. Neither choice resolves the harder question of what to do with the results, which is where AMORTAL sits on top of whichever route you take.
Optimization panels surface lots of slightly-off markers — how does AMORTAL help?
Advanced panels flag many markers just outside range, and the real risk is turning every abnormality into an action. AMORTAL evaluates whether a marker actually changes a realistic decision, whether the result is timely, whether a clinician should weigh in, and what downstream signal to watch — then ranks one next step instead of twelve. Restraint is the point: it's deliberately built to recommend doing nothing when that's the right call. Anything urgent goes to a clinician now.
Is a bigger panel better, and when should I retest after Mito or Marek?
Breadth helps for a baseline, but more markers also mean more borderline results that tempt over-reaction — bigger isn't automatically better. As for retesting, that depends on what you changed and how long it takes to show up in blood, not on the calendar. AMORTAL sets an expected window per marker and tells you when a retest would be informative versus premature, so you don't misread normal variation as a result.